Cocrystal Pharma, Inc. financial data

Symbol
COCP on Nasdaq
Location
19805 N. Creek Parkway, Bothell, WA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 466 % -45.4%
Debt-to-equity 44.4 % +112%
Return On Equity -130 % -37.1%
Return On Assets -89.8 % -14.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.8M shares +35.5%
Common Stock, Shares, Outstanding 13M shares +28.2%
Entity Public Float 18M USD -2.7%
Common Stock, Value, Issued 13K USD +30%
Weighted Average Number of Shares Outstanding, Basic 11M shares +8.03%
Weighted Average Number of Shares Outstanding, Diluted 11M shares +8.03%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.47M USD -62.9%
General and Administrative Expense 4.3M USD -22.6%
Operating Income (Loss) -9.77M USD +49.4%
Nonoperating Income (Expense) 97K USD -84.2%
Net Income (Loss) Attributable to Parent -9.67M USD +48.3%
Earnings Per Share, Basic 0 USD/shares +48.9%
Earnings Per Share, Diluted 0 USD/shares +48.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.86M USD -62.6%
Assets, Current 8.78M USD -38.4%
Property, Plant and Equipment, Net 106K USD -41.4%
Operating Lease, Right-of-Use Asset 1.47M USD -16.9%
Assets 10.4M USD -35.7%
Accounts Payable, Current 745K USD -13.3%
Employee-related Liabilities, Current 127K USD -31.4%
Liabilities, Current 1.52M USD -22%
Operating Lease, Liability, Noncurrent 1.26M USD -20.5%
Liabilities 2.78M USD -21.3%
Retained Earnings (Accumulated Deficit) -340M USD -2.93%
Stockholders' Equity Attributable to Parent 7.67M USD -39.6%
Liabilities and Equity 10.4M USD -35.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.94M USD +34.7%
Net Cash Provided by (Used in) Financing Activities -7K USD -16.7%
Net Cash Provided by (Used in) Investing Activities -8K USD +82.2%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 13M shares +28.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.94M USD +34.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 13.1M USD
Deferred Tax Assets, Valuation Allowance 35.2M USD +11.9%
Deferred Tax Assets, Gross 35.6M USD +11.5%
Operating Lease, Liability 1.58M USD -15.6%
Depreciation 45K USD
Payments to Acquire Property, Plant, and Equipment 8K USD -82.2%
Lessee, Operating Lease, Liability, to be Paid 1.83M USD -18.1%
Property, Plant and Equipment, Gross 2.09M USD +0.58%
Operating Lease, Liability, Current 326K USD +11.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 415K USD -0.96%
Lessee, Operating Lease, Liability, to be Paid, Year One 419K USD +2.95%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 242K USD -31.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 376K USD -9.4%
Deferred Tax Assets, Operating Loss Carryforwards 23.7M USD +7.58%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 249K USD -33.8%
Operating Lease, Payments 56K USD +12%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 35.2M USD +11.9%
Share-based Payment Arrangement, Expense 282K USD -19.2%
Interest Expense -220K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%